Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $282.7752W HIGH $448.21
Volume
625.60 K
Value Traded
339.91 M
Short % Float
3.37%
-4%Week
+5.53%1 Month
+12.23%3 Month
+39.83%6 Month
+9.67%5 Year
+8,954.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
41.78 B
EPS (TTM)
1.69
P/E Ratio
251.45
Ent. Value
46.12 B
Total Shares
98.18 M
Float Shares
98.11 M
Insiders
0.14%
Institutions
102.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
WAT Catalyst Timeline
Dated clinical, regulatory and corporate events for Waters Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Waters Corporation
175Total events
4Upcoming
20Tier-1 (high impact)
2011 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Everlywell partners with Waters Corporation for at-home HPV cervical cancer screening access
HPV cervical cancer screeningsource ↗
▲FDA ApprovalFDA Decision
FDA clearance of Onclarity HPV Self-Collection Kit
cervical cancer screeningsource ↗
▲Partnership / LicenseCorporate
Color Health partners with Waters Corporation to offer Onclarity HPV Self-Collection Kit
cervical cancer screeningsource ↗
▲Partnership / LicenseCorporate
Waters and IMU Biosciences announce strategic partnership to accelerate IMU's AI-powered HD Immunology platform
▲Product LaunchPost-Market
Global availability of BioResolve Peptide and GTxResolve Lipid Columns
◆Oral PresentationPresentation
Waters Corporation to present at Jefferies Global Healthcare Conference
▲FDA Filing AcceptedRegulatory Filing
FDA 510(k) clearance of BD BACTEC FXI Culture System
bloodstream infection diagnosticssource ↗
▲EU ApprovalEx-US Regulatory
CE marking under EU IVDR for BD BACTEC FXI Culture System
bloodstream infection diagnosissource ↗
▲Product LaunchPost-Market
Product available in Europe and Japan
bloodstream infection diagnosissource ↗
◆Oral PresentationPresentation
Showcase at ESCMID Global 2026 in Munich with live demonstrations
bloodstream infection diagnosissource ↗
▲FDA ApprovalFDA Decision
FDA approval of BD Onclarity HPV Assay with extended genotyping for at-home use
cervical cancer screeningsource ↗
▲FDA ApprovalFDA Decision
FDA clearance of Onclarity HPV Self-Collection Kit for at-home use
cervical cancer screeningsource ↗
◆Oral PresentationPresentation
Waters Corporation to present at TD Cowen Health Care Conference
▲Product LaunchPost-Market
Launch of 1 mm I.D. microflow LC columns with MaxPeak Premier Technology
◆AcquisitionCorporate
Expected close of Waters combination with BD's Biosciences & Diagnostic Solutions business
●Quarterly UpdateCorporate
Waters Corporation reports Q4 and full-year 2025 financial results
▲AcquisitionCorporate
Waters shareholders approve combination with BD's Biosciences & Diagnostic Solutions business
◆Oral PresentationPresentation
Waters Corporation to present at 44th Annual J.P. Morgan Healthcare Conference
▲Other Regulator MilestoneEx-US Regulatory
PMDA licensure in Japan
bloodstream infection diagnosticssource ↗
◆AcquisitionCorporate
Waters and BD's Biosciences & Diagnostic Solutions business to combine via Reverse Morris Trust
◆Oral PresentationPresentation
Waters Corporation to present at Jefferies Global Healthcare Conference in London
●Quarterly UpdateCorporate
Q4 2025 guidance: constant currency sales growth +5.0% to +7.0%, non-GAAP EPS $4.45-$4.55
◆Oral PresentationPresentation
Waters Corporation to present at Wells Fargo Healthcare Conference
▲Product LaunchPost-Market
Empower Software integration with MALS detectors available for peptide and protein workflows
◆Oral PresentationPresentation
Waters Corporation to present at Jefferies Global Healthcare Conference
▲Product LaunchPost-Market
Launch of BioResolve Protein A Affinity Columns with MaxPeak Premier Technology
▲Product LaunchBioResolvePost-Market
Lancement des colonnes d'affinité BioResolve pour la protéine A avec technologie MaxPeak
◆Oral PresentationPresentation
Waters Corporation to present at Leerink Partners Global Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How WAT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Waters Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every WAT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KUEBLER CHRISTOPHER ADirector | Option | 3,626 21,434 held | $136.43 | 08/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in WAT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 1.9 % (72.7 %) | 22.44 M | 59.83 K | 50.45% ( 20.06 K) |
WAT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-05-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How WAT ranks across every disease it competes in
Competitive Position is a premium feature
See how WAT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialWAT News
WAT▼ -0.1%today
Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
Waters Corporation has announced its Q3 2026 earnings conference call scheduled for November 3, 2026. The call will begin at 8:00 a.m. Eastern Time and will be available via a live webcast. A replay of the presentation will be accessible until December 1, 2026.
Read more →WATEverlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
Everlywell has partnered with Waters Corporation to launch the Onclarity™ HPV Self-Collection Kit, the most comprehensive at-home cervical cancer screening tool in the U.S. This initiative aims to facilitate access to cervical cancer screening for eligible patients, supporting health plans in their efforts to improve healthcare accessibility.
Read more →WATWaters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Waters Corporation has launched the BD FACSDiscover A7 Cell Analyzer, enhancing flow cytometry capabilities with advanced spectral resolution and standardization. This new device allows researchers to conduct experiments with over 50 parameters, improving data consistency across different users and instruments. The analyzer is designed to facilitate immunology research and drug development, making advanced technologies more accessible.
Read more →WATWaters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
Waters Corporation will have its CEO, Udit Batra, participate in a fireside chat at the J.P. Morgan U.S. All Stars Conference on September 23, 2026. The event will be webcast live and available for replay for 90 days. This participation underscores Waters' commitment to engaging with investors and stakeholders.
Read more →WATWellinks Appoints Andrew Agwunobi and Mike Waters to Board of Directors and Expands Management Team
Wellinks has appointed Andrew Agwunobi and Mike Waters to its Board of Directors, alongside three new leadership roles. These appointments aim to enhance the company's operational excellence and support its growth in virtual cardiopulmonary care. The new leaders bring extensive experience in healthcare and technology to strengthen Wellinks' impact on patient care.
Read more →WATLetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
LetsGetChecked has launched an FDA-cleared at-home HPV screening tool, marking a significant advancement in cervical cancer screening accessibility in the U.S. This tool is touted as the most comprehensive option available, allowing patients to manage their health from home. The partnership with Waters Corporation enhances the credibility and reach of this innovative solution.
Read more →WATWaters Corporation to Present at the Wells Fargo Healthcare Conference
Waters Corporation announced that its CEO, Udit Batra, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The event will be available via live webcast, with a replay accessible for 90 days. This participation underscores Waters' leadership in life sciences and commitment to innovation.
Read more →WAT▲ +5.7%on this news
Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
Waters Corporation reported strong financial results for Q2 2026, with total revenue of $1.645 billion, surpassing guidance. Organic revenue grew by 9% in constant currency, driven by significant growth in the Analytical Sciences Division. The company raised its full-year guidance, reflecting positive market conditions and effective execution of its growth strategy. However, GAAP EPS showed a loss due to acquisition-related costs.
Read more →WATWaters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
Waters Corporation has launched the Xevo TQ Absolute XR IVD Mass Spectrometer, enhancing its MassTrak IVD System portfolio. This new system offers five times greater sensitivity than its competitors, improving analytical performance for complex biological samples. It is designed for routine laboratory testing in women's health, cancer assessment, and toxicology, promising to boost laboratory productivity and reliability.
Read more →WATWaters Corporation Schedules Second Quarter 2026 Earnings Conference Call
Waters Corporation has announced its Q2 2026 earnings conference call scheduled for August 4, 2026. The call will take place at 8:00 a.m. Eastern Time, with a live webcast available on the company's Investor Relations website. A replay of the call will be accessible until September 1, 2026.
Read more →WATSNT Biotech Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
SNT Biotech has partnered with Waters Corporation to enhance access to at-home cervical cancer screenings through the FDA-cleared Onclarity™ HPV Self-Collection Kit. This initiative aims to address the significant barriers to screening faced by underserved populations, with a focus on improving completion rates and early detection of cervical cancer. The partnership combines education and infrastructure to facilitate better health outcomes for women.
Read more →WATColor Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
Color Health has launched the FDA-cleared Onclarity™ HPV Self-Collection Kit, enhancing at-home cervical cancer screening in the U.S. This innovative kit allows for comprehensive screening of high-risk HPV types and aims to improve accessibility for patients. The initiative is part of Color's broader cancer care program, which has shown a significant increase in screening adherence and faster diagnosis times.
Read more →WATIMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
IMU Biosciences has partnered with Waters Corporation to enhance its AI-driven immune mapping platform. This collaboration aims to analyze over 100 million data points from a single blood sample, improving early diagnosis and precision medicine. The partnership will leverage Waters' advanced technologies to expand IMU's immune dataset and establish new standards in immune profiling.
Read more →WATHighRes® and Waters Collaborate to Advance Drug Discovery through Robotic Automation
Waters Corporation is collaborating with HighRes® to enhance drug discovery processes through robotic automation. This partnership aims to streamline workflows and improve efficiency in pharmaceutical research. The collaboration highlights the ongoing trend of integrating advanced technologies in drug development.
Read more →WATWaters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis
Waters Corporation has launched the Coin Cell Differential Scanning Calorimeter (DSC), aimed at enhancing battery safety testing. This innovative device integrates thermal, evolved gas, and electrochemical analysis in one experiment, significantly reducing sample preparation time. It allows for direct testing of fully assembled coin cells, providing faster insights into battery performance and safety.
Read more →WATWaters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques—Waters Corporation (NYSE: WAT) today announced the...
Waters Corporation has announced the launch of its BioResolve Peptide and GTxResolve Lipid Columns, which are designed to significantly enhance the separation of impurities in GLP-1 peptides and lipid nanoparticles. This new technology promises up to three times faster characterization of GLP-1 and twice the speed for lipid component analysis, potentially reducing costs and improving regulatory compliance. The columns feature specialized surface chemistries and particle designs to optimize separation efficiency in both HPLC and U(H)PLC systems. Beginning June 9, 2026, these innovative solutions aim to address critical challenges faced in biopharmaceutical development.
Read more →WATWaters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics Waters Corporation (NYSE: WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k)...
Waters Corporation has announced that the BD BACTEC FXI Culture System has received FDA 510(k) clearance, allowing for its commercialization in the U.S. This automated blood culture system aims to enhance the speed and accuracy of diagnosing bloodstream infections. Clinical data indicates that it can reduce the mean time to detection by approximately three hours compared to its predecessor, which is critical for patient outcomes. The system features advanced automation and an innovative measurement capability designed to improve overall diagnostic reliability in high-throughput laboratories.
Read more →WATWaters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial OmicsAPAC - EnglishUSA - EnglishUSA - EnglishAPAC - Traditional Chinese
Waters Corporation has launched the Cyclic IMS P20 Mass Spectrometer, a cutting-edge platform designed for structural and spatial omics. This new instrument enhances sensitivity and resolution, allowing researchers to detect disease signals more effectively. The Cyclic IMS P20 combines multiple advanced techniques to provide comprehensive molecular insights, supporting accelerated discovery in biomedical research. It will be showcased at the ASMS 2026 conference and is set for global availability in September 2026.
Read more →About Waters Corporation
Headquarters34 MAPLE ST, MILFORD, MA, 01757
BIOPHARMAWATCH ELITE PLUS
Trade the next WAT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime